This is just to the best of my knowledge, but I believe the Valeant risk is now gone from PBP. Valeant sold their iNova subsidiary back in early June (
http://www.*.com/valeant-pharmaceuticals-selling-its-inova-business-for-930-million-2017-6?IR=T), who was the division that was distributing PBP's branded pharmaceuticals (and had some drugs being contract manufactured).
So I guess we don't have to worry about reconciling the Valeant risk...but now we have the private equity risk! I've tried to contact management and scour the internet to find any sort of iNova update post private equity acquisition but have been unable to find anything. Major risk obviously is they come in and slash and burn costs leading to lower sales and marketing efforts for PBP's products.
A huge risk, but given the sale only occurred in June I'm hoping that there has been little disruption to sales or contract manufacturing into the upcoming full year result.
